RxDoctor Payments DataLook up a doctor →

Kimberly Poarch

Medical · Dallas, TXNPI 1598908337

Payments from drug & device makers

$166,180in general payments, 2019–2025

Across 847 payments — averaging $196.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pharming Healthcare, Inc.$52K
  • Takeda Pharmaceuticals U.S.A., Inc.$40K
  • CSL Behring$35K
  • Biocryst US Sales Co., LLC$25K
  • AstraZeneca$3K
  • Novartis$2K
  • plus $10K from 37 others

What the payments were for

  • Consulting fees$46,78928%
  • Speaking & faculty fees$76,96246%
  • Travel & lodging$21,55413%
  • Food & beverage$20,59312%
  • Education$2820%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pharming Healthcare, Inc.109$51,962
Takeda Pharmaceuticals U.S.A., Inc.137$39,756
CSL Behring81$34,608
Biocryst US Sales Co., LLC109$25,425
AstraZeneca99$2,698
Novartis16$2,192
Cycle Pharmaceuticals Inc8$1,664
Regeneron Healthcare Solutions, Inc.53$1,590
Biocryst Pharmaceuticals, Inc.5$1,301
Sanofi37$889
GSK44$630
Genentech USA, Inc.13$487
Grifols USA, LLC22$470
Octapharma USA, Inc.16$403
Pfizer12$257
Amgen10$189
Kaleo, Inc.7$161
ARS Pharmaceuticals Operations, Inc.7$156
Insmed, Inc.7$144
Optinose US, Inc.4$133
ADMA Biomanufacturing LLC7$123
Alk-abello, Inc5$120
Sanofi-aventis U.S. LLC1$100
Boehringer Ingelheim4$98
Blueprint Medicines Corporation4$86
Ionis Pharmaceuticals, Inc.3$72
Teva Pharmaceuticals USA, Inc.4$60
Bio Products Laboratory USA, Inc.3$50
Kedrion Biopharma, Inc.2$47
Paratek Pharmaceuticals, Inc.2$45
Galderma Laboratories, L.p.2$39
Hospira, Inc.2$30
Covis Pharma GmbH2$28
Azurity Pharmaceuticals, Inc.1$25
Lilly USA, LLC1$22
Merck1$18
Tersera Therapeutics LLC1$15
Invivyd Inc1$15
USWM, LLC1$15
Hikma Pharmaceuticals USA1$15
Eyevance Pharmaceuticals LLC1$14
Organon1$14
Inspire Medical Systems, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$166,180 in reported general payments places this provider in the 95th percentile of 1,490 medical providers in Texas.

See all medical providers in Texas →

Most prescribed under Part D

DrugClaimsCost to plans & patients
TakhzyroLanadelumab-Flyo21$1,037,047
OrladeyoBerotralstat Hydrochloride22$963,186
HaegardaC1 Esterase Inhibitor15$765,723
Dupixent SyringeDupilumab15$54,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Takhzyro$39,756$1,037,04721 claims
Biocryst US Sales Co., LLCOrladeyo$25,425$963,18622 claims
CSL BehringHaegarda$34,608$765,72315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,490 medical providers in Texas.

Other medical in Dallas

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →